Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer

Clinical Infectious Diseases

Volumn 54, Issue 12, 2012, Pages 1785-1792

  Theuretzbacher, Ursula ^a  

^a Center For Anti Infective Agents Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; COLISTIN; DAPTOMYCIN; ERTAPENEM; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TELAVANCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CACHEXIA; CANCER PATIENT; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; EFFUSION; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; HYPOALBUMINEMIA; IMMUNE DEFICIENCY; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEOPLASM; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROBABILITY OF TARGET ATTAINMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84861512467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis210     Document Type: Article

References (62)

1. Thirumala R, Ramaswamy M, Chawla S. Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin 2010; 26:59-91.
2. Safdar A, Bodey G, Armstrong D. Infections in patients with cancer: overview. In: Safdar A, ed. Principles and practice of cancer infectious diseases. 1st ed. Vol 3. New York: Humana Press, 2011:3-15.
3. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011; 53:798-806.
4. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14:107-17.
5. Theuretzbacher U, Zeitlinger M. Antibacterial distribution and drug-drug interactions in cancer patients. In: Safdar A, ed. Principles and practice of cancer infectious diseases. 1st ed. Vol 3. New York: Humana Press, 2011:443-54.
6. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86. (Pubitemid 44968990)
7. Lortholary O, Lefort A, Tod M, Chomat A-M, Darras-Joly C, Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008; 8:612-20.
8. Nyhlen A, Ljungber B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 2001; 33:222-6. (Pubitemid 32258033)
9. Rafailidis PI, Kouranos VD, Christodoulou C, Falagas ME. Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? Expert Rev Anti Infect Ther 2009; 7:415-22.
10. Daenen S, Erjavec Z, Uges D, De Vries-Hospers H, De Jonge P, Halie M. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:188-92.
11. del Mar Fernández de Gatta M, Buelga DS, Navarro AS, Dominguez-Gil A, Garća MJ. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009; 48:273-80.
12. Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol 2011; 12:2030-6.
13. Romano S, de Gatta MMF, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44: 235-42. (Pubitemid 29389287)
14. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44:1009-34. (Pubitemid 41356389)
15. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009; 53:428-34.
16. Zeitlinger MA, Derendorf H, Mouton JW, et al. Protein binding-do we ever learn? Antimicrob Agents Chemother 2011; 55:3067-74.
17. Benoni G, Arosio E, Cuzzolin L, Vaona B, Raimondi MG, Lechi A. Penetration of ceftriaxone into human pleural fluid. Antimicrob Agents Chemother 1986; 29:906-8. (Pubitemid 16118334)
18. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50:99-110.
19. He X, Clarke SJ, McLachlan AJ. Clinical pharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriatr Res 2011; 2011:628670.
20. Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011; 139:1210-20.
21. Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011; 7:226-35.
22. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 2007; 7:498-504. (Pubitemid 47560214)
23. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61:235-7.
24. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50:2455-63. (Pubitemid 43993186)
25. Zeitlinger MA, Erovic BM, Sauermann R, Georgopoulos A, Muller M, Joukhadar C. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother 2005; 56:703-8. (Pubitemid 41487772)
26. Drusano GL, Fregeau C, Liu W, Brown DL, Louie A. Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 2010; 54:4368-72.
27. Drusano GL, VanScoy B, Liu W, Fikes S, Brown D, Louie A. Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia. Antimicrob Agents Chemother 2011; 55:2693-5.
28. Andes DR, Van Ogtrop ML, Craig WA. Impact of neutrophils on the in vivo activity of fluoroquinolones. In: Program and abstracts of the 37th Meeting of the Infectious Diseases Society of America (Philadelphia). Arlington, VA: Infectious Diseases Society of America, 1999.
29. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8. (Pubitemid 40052375)
30. Jaksic B, Martinelli G, Oteyza JP, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607. (Pubitemid 43271371)
31. Rolston KV. New antimicrobial agents for the treatment of bacterial infections in cancer patients. Hematol Oncol 2009; 27:107-14.
32. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-93.
33. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin 2011; 27:77-93.
34. Lamoth F, Buclin T, Csajka C, Pascual A, Calandra T, Marchetti O. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53:785-7.
35. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-60. (Pubitemid 47378891)
36. Conil J-M, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71:61-71.
37. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52: 969-74.
38. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
39. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on daptomycin. Clin Microbiol Infect 2006; 12:599-601.
40. Ambrose PG, Forrest A, Okusanya OO, Van Wart SA, Bhavnani SM. Pharmacokinetic-pharmacodynamic target attainment of daptomycin against staphylococcus aureus. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2008.
41. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23. (Pubitemid 38054365)
42. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54:4605-10.
43. Benko R, Matuz M, Doro P, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilatorassociated pneumonia. Int J Antimicrob Agents 2007; 30:162-8. (Pubitemid 46992714)
44. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcomebased Monte Carlo simulations. Antimicrob Agents Chemother 2005; 49:4009-14. (Pubitemid 41400939)
45. Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents 2011; 38:231-6.
46. Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011; 66:227-31.
47. Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion b-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010; 44:929-35.
48. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007; 44:357-63. (Pubitemid 46147617)
49. Al-Kofide H, Zaghloul I, Al-Naim L. Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract 2010; 16:245-50.
50. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011; 55:2528-31.
51. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003; 47:548-53. (Pubitemid 36158080)
52. Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011; 55:1867-73.
53. Pea F, Poz D, Viale P, Pavan F, Furlanut M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 2006; 58:380-6. (Pubitemid 44294951)
54. Riou M, Carbonnelle S, Avrain L, et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010; 36:513-22.
55. van Hees BC, Tersmette M, Willems RJ, de Jong B, Biesma D, van Hannen EJ. Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical Escherichia coli isolates from haematology patients receiving ciprofloxacin prophylaxis. J Antimicrob Chemother 2011; 66:1739-44.
56. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007; 45(Suppl 2):S129-36. (Pubitemid 47328627)
57. Macia MD, Borrell N, Segura M, Gomez C, Perez JL, Oliver A. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:975-83. (Pubitemid 43327803)
58. Louie A, Grasso C, Bahniuk N, et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 2010; 54:2646-54.
59. Boak LM, Li J, Rayner CR, Nation RL. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 2007; 51:1287-92. (Pubitemid 46586807)
60. Zelenitsky S, Alkurdi N, Weber Z, Ariano R, Zhanel G. Preferential emergence of reduced vancomycin susceptibility in healthcareassociated methicillin-resistant Staphylococcus aureus during continuous infusion vancomycin therapy in an in vitro dynamic model. Antimicrob Agents Chemother 2011; 55:3627-30.
61. Drusano GL, Liu W, Brown DL, Rice LB, Louie A. Impact of shortcourse quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 2009; 199:219-26.
62. Bakker-Woudenberg IA, ten Kate MT, Goessens WH, Mouton JW. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 2006; 50:2919-25. (Pubitemid 44396393)